Lindsey Adair MacFarlane, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis, Knee | 14 | 2023 | 1222 | 3.280 |
Why?
|
| Synovitis | 4 | 2023 | 209 | 2.100 |
Why?
|
| Knee Injuries | 4 | 2023 | 490 | 1.390 |
Why?
|
| Knee Joint | 6 | 2023 | 1679 | 1.360 |
Why?
|
| Dermatomyositis | 2 | 2016 | 223 | 0.920 |
Why?
|
| Arthralgia | 2 | 2018 | 456 | 0.890 |
Why?
|
| Hyperuricemia | 2 | 2016 | 208 | 0.850 |
Why?
|
| Physical Therapy Modalities | 4 | 2023 | 547 | 0.800 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2021 | 1341 | 0.790 |
Why?
|
| Edema | 3 | 2019 | 790 | 0.700 |
Why?
|
| Arthroscopy | 3 | 2022 | 924 | 0.660 |
Why?
|
| Gout | 2 | 2016 | 556 | 0.650 |
Why?
|
| Vitamin D | 3 | 2021 | 3211 | 0.650 |
Why?
|
| Arthroplasty, Replacement | 1 | 2019 | 336 | 0.520 |
Why?
|
| Angioedema | 1 | 2016 | 187 | 0.490 |
Why?
|
| Antirheumatic Agents | 3 | 2023 | 1335 | 0.470 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2023 | 3695 | 0.460 |
Why?
|
| Diabetes Complications | 1 | 2019 | 1359 | 0.420 |
Why?
|
| Vitamins | 1 | 2020 | 1608 | 0.410 |
Why?
|
| Perioperative Care | 1 | 2019 | 997 | 0.410 |
Why?
|
| Dietary Supplements | 3 | 2021 | 3294 | 0.400 |
Why?
|
| Osteoarthritis | 1 | 2019 | 1034 | 0.400 |
Why?
|
| Cartilage, Articular | 1 | 2018 | 1095 | 0.390 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 4933 | 0.380 |
Why?
|
| Injections, Intra-Articular | 2 | 2022 | 278 | 0.380 |
Why?
|
| Hyperglycemia | 1 | 2019 | 1368 | 0.370 |
Why?
|
| Uric Acid | 1 | 2014 | 760 | 0.330 |
Why?
|
| Menisci, Tibial | 2 | 2022 | 269 | 0.300 |
Why?
|
| Protein Kinases | 1 | 2014 | 1638 | 0.280 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2018 | 1457 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2023 | 35342 | 0.260 |
Why?
|
| Pain | 6 | 2023 | 4961 | 0.250 |
Why?
|
| Blood Glucose | 1 | 2019 | 6249 | 0.250 |
Why?
|
| Synovial Fluid | 2 | 2023 | 394 | 0.240 |
Why?
|
| Hypoglycemic Agents | 2 | 2014 | 2866 | 0.240 |
Why?
|
| Physicians | 1 | 2022 | 4554 | 0.230 |
Why?
|
| Middle Aged | 21 | 2023 | 213127 | 0.220 |
Why?
|
| Aged | 17 | 2023 | 162944 | 0.210 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3151 | 0.210 |
Why?
|
| Databases, Factual | 1 | 2016 | 7716 | 0.190 |
Why?
|
| Arthritis, Psoriatic | 1 | 2023 | 215 | 0.190 |
Why?
|
| CD40 Ligand | 3 | 2007 | 526 | 0.180 |
Why?
|
| Deglutition Disorders | 2 | 2016 | 604 | 0.180 |
Why?
|
| Insulin | 1 | 2014 | 6575 | 0.180 |
Why?
|
| Male | 23 | 2023 | 349538 | 0.170 |
Why?
|
| Atherosclerosis | 7 | 2010 | 3428 | 0.170 |
Why?
|
| TNF Receptor-Associated Factor 1 | 2 | 2010 | 50 | 0.170 |
Why?
|
| Humans | 37 | 2023 | 742088 | 0.170 |
Why?
|
| Leukocyte Count | 1 | 2023 | 1583 | 0.170 |
Why?
|
| Bone Diseases | 1 | 2022 | 416 | 0.160 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2019 | 227 | 0.160 |
Why?
|
| Patient Preference | 2 | 2022 | 886 | 0.160 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2017 | 54 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 5522 | 0.150 |
Why?
|
| Pain Measurement | 2 | 2018 | 3418 | 0.150 |
Why?
|
| Inflammation | 5 | 2023 | 10578 | 0.150 |
Why?
|
| Female | 20 | 2023 | 379592 | 0.150 |
Why?
|
| Ontario | 1 | 2018 | 381 | 0.150 |
Why?
|
| Glucocorticoids | 2 | 2016 | 2107 | 0.140 |
Why?
|
| Qualitative Research | 2 | 2022 | 2680 | 0.140 |
Why?
|
| Diet | 1 | 2014 | 7923 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 5724 | 0.140 |
Why?
|
| Algorithms | 1 | 2016 | 13853 | 0.130 |
Why?
|
| Methotrexate | 2 | 2023 | 1720 | 0.120 |
Why?
|
| Biopsy | 2 | 2016 | 6756 | 0.120 |
Why?
|
| Biological Products | 1 | 2023 | 856 | 0.120 |
Why?
|
| Muscle Weakness | 1 | 2016 | 414 | 0.110 |
Why?
|
| Janus Kinases | 1 | 2014 | 244 | 0.110 |
Why?
|
| Thyrotropin | 1 | 2016 | 850 | 0.110 |
Why?
|
| Obesity | 1 | 2014 | 12705 | 0.100 |
Why?
|
| Neck | 1 | 2016 | 693 | 0.100 |
Why?
|
| Exanthema | 1 | 2016 | 488 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 12958 | 0.090 |
Why?
|
| Eye Diseases | 1 | 2016 | 670 | 0.090 |
Why?
|
| Receptors, CCR1 | 1 | 2009 | 33 | 0.090 |
Why?
|
| Mast Cells | 2 | 2007 | 1544 | 0.090 |
Why?
|
| Medicare | 2 | 2019 | 6532 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 4438 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2020 | 12017 | 0.090 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2010 | 1181 | 0.090 |
Why?
|
| Cystatin C | 1 | 2010 | 250 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2010 | 686 | 0.080 |
Why?
|
| Drug Design | 1 | 2014 | 1078 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2023 | 62966 | 0.080 |
Why?
|
| Pancreatic Elastase | 1 | 2007 | 135 | 0.080 |
Why?
|
| TNF Receptor-Associated Factor 5 | 1 | 2007 | 7 | 0.080 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2007 | 40 | 0.070 |
Why?
|
| Tunica Intima | 1 | 2009 | 464 | 0.070 |
Why?
|
| Pyrroles | 1 | 2014 | 1143 | 0.070 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2007 | 59 | 0.070 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2007 | 55 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2022 | 3915 | 0.070 |
Why?
|
| Angiotensin II | 1 | 2010 | 881 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 24913 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2022 | 57683 | 0.070 |
Why?
|
| Linear Models | 1 | 2016 | 5948 | 0.070 |
Why?
|
| Macrophage-1 Antigen | 1 | 2007 | 290 | 0.070 |
Why?
|
| Aortic Diseases | 2 | 2009 | 741 | 0.070 |
Why?
|
| Vasculitis | 1 | 2010 | 521 | 0.070 |
Why?
|
| Interleukin-18 | 1 | 2007 | 248 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 2749 | 0.070 |
Why?
|
| Piperidines | 1 | 2014 | 1602 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 9941 | 0.070 |
Why?
|
| Aorta | 2 | 2009 | 2057 | 0.060 |
Why?
|
| Mass Screening | 1 | 2019 | 5238 | 0.060 |
Why?
|
| Disease Progression | 2 | 2018 | 13256 | 0.060 |
Why?
|
| Age Factors | 3 | 2019 | 18355 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 4147 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12242 | 0.060 |
Why?
|
| Risk Factors | 4 | 2023 | 72145 | 0.050 |
Why?
|
| Sex Factors | 2 | 2014 | 10392 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2723 | 0.050 |
Why?
|
| Interleukin-6 | 4 | 2019 | 3199 | 0.050 |
Why?
|
| United States | 3 | 2019 | 69693 | 0.050 |
Why?
|
| Macrophages | 4 | 2010 | 5655 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2014 | 2933 | 0.050 |
Why?
|
| Knee | 1 | 2023 | 274 | 0.050 |
Why?
|
| Receptors, LDL | 3 | 2010 | 475 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 9274 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 15056 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2010 | 3455 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 15530 | 0.040 |
Why?
|
| Adult | 5 | 2022 | 213712 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4440 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 13019 | 0.040 |
Why?
|
| Metformin | 1 | 2005 | 829 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 425 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2007 | 1889 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 1149 | 0.040 |
Why?
|
| Arteries | 1 | 2023 | 1118 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 19862 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 40450 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 357 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2023 | 77098 | 0.040 |
Why?
|
| Focus Groups | 1 | 2022 | 1320 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2005 | 2500 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 2763 | 0.040 |
Why?
|
| Mice, Knockout | 5 | 2010 | 14554 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2023 | 1820 | 0.030 |
Why?
|
| Hypertension | 1 | 2016 | 8455 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 1788 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2023 | 4414 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 17400 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 13655 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2023 | 1575 | 0.030 |
Why?
|
| Mice, Mutant Strains | 2 | 2010 | 1866 | 0.030 |
Why?
|
| Animals | 9 | 2014 | 168561 | 0.030 |
Why?
|
| Saphenous Vein | 2 | 2007 | 531 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 21596 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 6483 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 5 | 2010 | 21821 | 0.030 |
Why?
|
| Cytokines | 1 | 2007 | 7317 | 0.030 |
Why?
|
| Mice | 8 | 2010 | 81045 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 23387 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2009 | 209 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2005 | 1504 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 3766 | 0.020 |
Why?
|
| Decision Making | 1 | 2022 | 3869 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 6454 | 0.020 |
Why?
|
| Diet, Atherogenic | 1 | 2007 | 95 | 0.020 |
Why?
|
| Transplants | 1 | 2009 | 208 | 0.020 |
Why?
|
| Foam Cells | 1 | 2007 | 71 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2010 | 669 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2007 | 231 | 0.020 |
Why?
|
| Texas | 1 | 2007 | 392 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2009 | 1183 | 0.020 |
Why?
|
| Elastin | 1 | 2007 | 305 | 0.020 |
Why?
|
| Rheology | 1 | 2007 | 345 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2007 | 821 | 0.020 |
Why?
|
| Chemokines | 1 | 2010 | 954 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2007 | 791 | 0.020 |
Why?
|
| Cricetulus | 1 | 2007 | 817 | 0.020 |
Why?
|
| Peritonitis | 1 | 2007 | 365 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 1438 | 0.020 |
Why?
|
| CHO Cells | 1 | 2007 | 1407 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2007 | 675 | 0.010 |
Why?
|
| Cell Proliferation | 2 | 2010 | 10472 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2022 | 21719 | 0.010 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 4455 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 1599 | 0.010 |
Why?
|
| Peroxidase | 1 | 2007 | 610 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 774 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 13921 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2010 | 3139 | 0.010 |
Why?
|
| Cricetinae | 1 | 2007 | 2471 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2005 | 689 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 3123 | 0.010 |
Why?
|
| Actins | 1 | 2010 | 2120 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 2513 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2010 | 19223 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2005 | 1262 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 2005 | 645 | 0.010 |
Why?
|
| Leukocytes | 1 | 2010 | 2039 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 4229 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2007 | 1080 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 820 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2007 | 5180 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2007 | 3199 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39004 | 0.010 |
Why?
|
| Time Factors | 1 | 2019 | 40054 | 0.010 |
Why?
|
| Cell Movement | 1 | 2010 | 5212 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 3504 | 0.010 |
Why?
|
| Monocytes | 1 | 2007 | 2593 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 6171 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 2502 | 0.010 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 2337 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 2938 | 0.010 |
Why?
|
| Lipids | 1 | 2007 | 3302 | 0.010 |
Why?
|
| Life Style | 1 | 2007 | 3824 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 5872 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 9735 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 7790 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 9715 | 0.010 |
Why?
|
| Glucose | 1 | 2005 | 4391 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2010 | 11470 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 9581 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 11695 | 0.000 |
Why?
|